OptimizeRx (OPRX) reported Q4 2025 revenue of USD 32.2 million, with gross profit up 9% to USD 24.1 million. Q4 net income was USD 5.0 million and adjusted EBITDA reached USD 12.0 million. For FY 2025, OptimizeRx posted revenue of USD 109.4 million (+19%), gross profit of USD 73.6 million, net income of USD 5.1 million, and adjusted EBITDA of USD 24.3 million. Cash and cash equivalents were USD 23.4 million at December 31, 2025, and net cash provided by operating activities was USD 18.7 million for FY 2025. The company updated FY 2026 guidance to revenue of USD 109 million to USD 114 million and adjusted EBITDA of USD 21 million to USD 25 million. OptimizeRx also said it paid down an incremental USD 2.0 million in term-loan principal during Q4 and its board authorized a USD 10.0 million share repurchase program, effective March 12, 2026 through March 15, 2027 (or until the limit is reached). Management cited increased market volatility tied in part to uncertainty around Most Favored Nation pricing, and highlighted its AI-driven engagement platform, including the Dynamic Audience Activation Platform and Micro-Neighborhood Targeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051601PRIMZONEFULLFEED9666719) on March 05, 2026, and is solely responsible for the information contained therein.
Comments